$39.59
1.10% yesterday
Nasdaq, Sep 03, 10:00 pm CET

Collegium Pharmaceutical, Inc. Target price 2025 - Analyst rating & recommendation

Collegium Pharmaceutical, Inc. Classifications & Recommendation:

Buy
82%
Hold
18%

Collegium Pharmaceutical, Inc. Price Target

Target Price $45.90
Price $39.59
Potential
Number of Estimates 7
7 Analysts have issued a price target Collegium Pharmaceutical, Inc. 2026 . The average Collegium Pharmaceutical, Inc. target price is $45.90. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 9 Analysts recommend Collegium Pharmaceutical, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Collegium Pharmaceutical, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Collegium Pharmaceutical, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 631.45 771.84
11.41% 22.23%
EBITDA Margin 53.70% 57.83%
6.28% 7.70%
Net Margin 10.96% 34.44%
28.95% 214.31%

7 Analysts have issued a sales forecast Collegium Pharmaceutical, Inc. 2025 . The average Collegium Pharmaceutical, Inc. sales estimate is

$772m
Unlock
. This is
9.17% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$812m 14.85%
Unlock
, the lowest is
$728m 2.99%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $631m 11.41%
2025
$772m 22.23%
Unlock
2026
$793m 2.78%
Unlock
2027
$735m 7.39%
Unlock
2028
$684m 6.97%
Unlock
2029
$750m 9.77%
Unlock
2030
$788m 4.97%
Unlock
2031
$854m 8.38%
Unlock
2032
$574m 32.78%
Unlock

7 Analysts have issued an Collegium Pharmaceutical, Inc. EBITDA forecast 2025. The average Collegium Pharmaceutical, Inc. EBITDA estimate is

$446m
Unlock
. This is
32.45% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$467m 38.70%
Unlock
, the lowest is
$423m 25.44%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $339m 4.42%
2025
$446m 31.66%
Unlock
2026
$438m 1.91%
Unlock
2027
$382m 12.78%
Unlock
2028
$367m 3.96%
Unlock
2029
$381m 3.74%
Unlock
2030
$404m 6.23%
Unlock

EBITDA Margin

2024 53.70% 6.28%
2025
57.83% 7.70%
Unlock
2026
55.19% 4.57%
Unlock
2027
51.98% 5.82%
Unlock
2028
53.66% 3.23%
Unlock
2029
50.71% 5.50%
Unlock
2030
51.33% 1.22%
Unlock

7 Collegium Pharmaceutical, Inc. Analysts have issued a net profit forecast 2025. The average Collegium Pharmaceutical, Inc. net profit estimate is

$266m
Unlock
. This is
632.89% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$347m 856.27%
Unlock
, the lowest is
$216m 495.86%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $69.2m 43.67%
2025
$266m 284.19%
Unlock
2026
$268m 0.96%
Unlock
2027
$235m 12.53%
Unlock
2028
$200m 14.82%
Unlock
2029
$253m 26.34%
Unlock
2030
$269m 6.43%
Unlock

Net Margin

2024 10.96% 28.95%
2025
34.44% 214.31%
Unlock
2026
33.83% 1.77%
Unlock
2027
31.95% 5.56%
Unlock
2028
29.25% 8.45%
Unlock
2029
33.67% 15.11%
Unlock
2030
34.14% 1.40%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 1.71 8.43
48.70% 392.98%
P/E 4.65
EV/Sales 2.38

7 Analysts have issued a Collegium Pharmaceutical, Inc. forecast for earnings per share. The average Collegium Pharmaceutical, Inc. EPS is

$8.43
Unlock
. This is
816.30% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$10.99 1,094.57%
Unlock
, the lowest is
$6.85 644.57%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $1.71 48.70%
2025
$8.43 392.98%
Unlock
2026
$8.51 0.95%
Unlock
2027
$7.44 12.57%
Unlock
2028
$6.34 14.78%
Unlock
2029
$8.01 26.34%
Unlock
2030
$8.52 6.37%
Unlock

P/E ratio

Current 42.57 173.36%
2025
4.65 89.08%
Unlock
2026
4.60 1.08%
Unlock
2027
5.26 14.35%
Unlock
2028
6.18 17.49%
Unlock
2029
4.89 20.87%
Unlock
2030
4.60 5.93%
Unlock

Based on analysts' sales estimates for 2025, the Collegium Pharmaceutical, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.59 1.89%
2025
2.38 8.24%
Unlock
2026
2.31 2.71%
Unlock
2027
2.50 7.98%
Unlock
2028
2.68 7.49%
Unlock
2029
2.44 8.91%
Unlock
2030
2.33 4.73%
Unlock
2031
2.15 7.72%
Unlock
2032
3.20 48.76%
Unlock

P/S ratio

Current 1.74 18.79%
2025
1.60 8.40%
Unlock
2026
1.56 2.71%
Unlock
2027
1.68 7.98%
Unlock
2028
1.80 7.49%
Unlock
2029
1.64 8.91%
Unlock
2030
1.57 4.73%
Unlock
2031
1.45 7.73%
Unlock
2032
2.15 48.76%
Unlock

Current Collegium Pharmaceutical, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Piper Sandler
Locked
Locked
Locked May 09 2025
Needham
Locked
Locked
Locked Apr 09 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 24 2025
Piper Sandler
Locked
Locked
Locked Feb 04 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 10 2025
Needham
Locked
Locked
Locked Jan 10 2025
Piper Sandler
Locked
Locked
Locked Oct 11 2024
Analyst Rating Date
Locked
Piper Sandler:
Locked
Locked
May 09 2025
Locked
Needham:
Locked
Locked
Apr 09 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 24 2025
Locked
Piper Sandler:
Locked
Locked
Feb 04 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 10 2025
Locked
Needham:
Locked
Locked
Jan 10 2025
Locked
Piper Sandler:
Locked
Locked
Oct 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today